Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 2, 2006, Pages 143-156

  Sandstrom M ^a,e   Lindman, H ^b   Nygren, P ^b   Johansson, M ^c   Bergh, J ^d   Karlsson, M O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Apoteksbolaget AB   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

4 hydroxycyclophosphamide; Epirubicin; Fluorouracil; Fluorouracil epirubicin cyclophosphamide; Haematological toxicity; Pharmacokinetics; Pharmacokinetics pharmacodynamic model

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ALBUMIN; BETAMETHASONE; BILIRUBIN; CIPROFLOXACIN; CREATININE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANOCYT; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TROPISETRON;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BODY SURFACE; BODY WEIGHT; BREAST CANCER; COMPARTMENT MODEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MONITORING; HUMAN; MAJOR CLINICAL STUDY; MITOSIS; PHARMACODYNAMICS; POPULATION RESEARCH; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS;

EID: 33646517096     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0140-2     Document Type: Article

References (48)

1. Beal S, Sheiner L (1999) NONMEM users guides. University of California, San Fransicso, CA
2. Bergh J, Wiklund T, Erikstein B, Fornander T, Bengtsson NO, Malmstrom P, Kellokumpu-Lehtinen P, Anker G, Bennmarker H, Wilking N (1998) Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401. Ann Oncol 9:403
3. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356:1384
4. Cockroft D, Gault M (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31
5. De Bruijn EA, Driessen OM, Hermans J (1991) The CMF-regimen. Toxicity patterns following stepwise combinations of cyclophosphamide, methotrexate and fluorouracil. Int J Cancer 48:67
6. Del Mastro L, Venturini M, Lionetto R, Carnino F, Guarneri D, Gallo L, Contu A, Pronzato P, Vesentini L, Bergaglio M, Comis S, Rosso R (2001) Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian gruppo oncologico nord-ouest-mammella inter gruppo group. J Clin Oncol 19:2213
7. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215
8. Dobbs NA, Twelves CJ, Gregory W, Cruickshanka C, Richards MA, Rubens RD (2003) Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer 39:580
9. Evans WE, Relling MV (1989) Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 16:327
10. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499
11. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037
12. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, Demard F (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899
13. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439
14. Freyer G, Tranchand B, Ligneau B, Ardiet C, Souquet PJ, Court-Fortune I, Riou R, Rebattu P, Boissel JP, Trillet-Lenoir V, Girard P (2000) Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol 50:315
15. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 15, 20(24):4713
16. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17:1105
17. Grochow LB, Noe DA, Dole GB, Rowinsky EK, Ettinger DS, Graham ML, McGuire WP, Donehower RC (1989) Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. J Natl Cancer Inst 81:124
18. Grochow LB, Baraldi C, Noe D (1990) Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 82:323
19. Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14:2590
20. Gurney HP, Ackland S, Gebski V, Farrell G (1998) Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 16:2299
21. Hansen RM, Ryan L, Anderson T, Krzywda B, Quebbeman E, Benson A III, Haller DG, Tormey DC (1996) Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88:668
22. Henderson IC, Hayes DF, Gelman R (1988) Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 6:1501
23. Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS, Mouridsen HT (1991) A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 28:465
24. Jonsson EN, Karlsson MO (1998) Automated covariate model building within NONMEM. Pharm Res 15:1463
25. Karlsson MO, Sheiner LB (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21:735
26. Kwon CH, Maddison K, LoCastro L, Borch RF (1987) Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin. Cancer Res 47:1505
27. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A et al (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13:1303
28. Levine MN, Bramwell VH, Pritchard KI, Morris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651
29. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7:425
30. Microsoft Excel 2000 (1999) Microsoft Corporation
31. Milano G, Etienne MC (1994) Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 4:301
32. Moore MJ, Theissen JJ (1992) Cytotoxics and irreversible effects. In: van Boxtel CJ, Holford NHG, Danhof M (eds) The in vivo study of drug action. Elsevier Science Publisher B. V., Amsterdam, p 377
33. Moore MJ, Erlichman C, Thiessen JJ, Bunting PS, Hardy R, Kerr I, Soldin S (1994) Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother Pharmacol 33:472
34. Plosker GL, Faulds D (1993) Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45:788
35. Ralph LD, Thomson AH, Dobbs NA, Twelves C (2003) A population model of epirubicin pharmacokinetics and application to dosage guidelines. Cancer Chemother Pharmacol 52:34
36. Riccardi A, Giordano M, Brugnatelli S, Ucci G, Danova M, Mora O, Fava S, Ascari E (1995) Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: a randomised study in advanced breast cancer (letter). Eur J Cancer 31A:1549
37. Robert J (1994) Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 26:428
38. Rodman JH, Abromowitch M, Sinkule JA, Hayes FA, Rivera GK, Evans WE (1987) Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 5:1007
39. Rodman JH, Relling MV, Stewart CF, Synold TW, McLeod H, Kearns C, Stute N, Crom WR, Evans WE (1993) Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 20:18
40. Sandstrom M, Freijs A, Larsson R, Nygren P, Fjallskog ML, Bergh J, Karlsson MO (1996) Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 14:1581
41. Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO (2005) Haematological toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Onc 23:413
42. Sawyer M, Ratain MJ (2001) Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171
43. Simonsen LE, Wahlby U, Sandstrom M, Freijs A, Karlsson MO (2000) Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats. Anticancer Res 20:1519
44. Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Fety-Deporte R, Lafont T, Gamelin E, Bugat R, Canal P, Chatelut E (2000) Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther 68:270
45. Twelves CJ, Dobbs NA, Michael Y, Summers LA, Gregory W, Harper PG, Rubens RD, Richards MA (1992) Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 66:765
46. Van der Wall E, Rutgers EJ, Holtkamp MJ, Baars JW, Schornagel JH, Peterse JL, Beijnen JH, Rodenhuis S (1996) Efficacy of up-front 5-fluorouracil- epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. Br J Cancer 73:1080
47. Venturini M, Del Mastro L, Testore F, Danova M, Garrone O, Lanfranco C, Latini F, Sertoli MR, Lionetto R, Queirolo P, Ardizzoni A, Rosso R (1996) Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5- fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer. Cancer Chemother Pharmacol 38:487
48. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD, Idle JR (1995) Cyclophosphamide metabolism in children. Cancer Res 55:803